NBIX Stock Analysis: Buy, Sell, or Hold?
NBIX - Neurocrine Biosciences Inc
$159.95
-1.37 (-0.85%)
▼
5d:
+6.93%
30d:
+21.69%
90d:
+29.94%
HOLD
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 05, 2026
0d
Smart Money Accumulation
NBIX is down 4.2% this week, but smart money is accumulating calls. Top strike: $160 2026-06-18 with 166 OI. Call ratio: 84% View Scanner →
Strength: 5.4/10
Get Alerted When NBIX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: NBIX is 10.3% above its trading range ($144.98). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: NBIX is 10.3% above its trading range ($144.98). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$340.20
Based on 13.9% avg growth
INTRINSIC VALUE TODAY
$211.24
24.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NBIX is currently trading at $159.95, which is considered extended relative to its 30-day fair value range of $126.07 to $144.98. The stock's valuation (Forward PE: 12.7) is in line with its historical norms (14.1). Remarkably, the market is currently pricing in an annual earnings decline of 3.4% over the next few years. This pessimistic expectation contrasts with the company's recent 2310.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, NBIX is showing sideways momentum. The price is approaching resistance at $162.39. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: NBIX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $190.99 (+18.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NBIX is showing sideways momentum. The price is approaching resistance at $162.39. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: NBIX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $190.99 (+18.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$126.07 -
$144.98
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
50.0%
Protect Your Profits
NBIX is technically overbought (RSI 78). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price significantly overextended (+10.3% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($190.99)
Trading Range Analysis
30-Day Trading Range
$126.07 -
$144.98
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$129.86
Resistance Level
$162.39
Current Trend
Sideways
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.70
Wall Street Target
$190.99
(+18.4%)
Revenue Growth (YoY)
42.2%
Earnings Growth (YoY)
2310.5%
Profit Margin
21.6%
Valuation Discount vs History
-3.4% cheaper
PE vs Historical
12.7 vs 14.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.4%
(market-implied from PE analysis)
1-Year Target
$155.84
(-3%)
2-Year Target
$150.54
(-7%)
3-Year Target
$145.42
(-10%)
3-Yr Target (if PE normalizes)
(PE: 13→14)
$161.50
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 23.8%)
$531.06
(+229%)
Base:
(SPY PE: 12.7, Growth: 23.8%)
$305.92
(+90%)
Bear:
(PE: 10.8, Growth: 23.8%)
$260.03
(+61%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (25x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 24.70 | Current EPS (TTM): $6.50
Bull Case
$345.17
(+114%)
Analyst growth 95.5%, PE expands to 27.2
Base Case
$313.79
(+95%)
Market implied 95.5%, PE stable at 24.7
Bear Case
$109.16
(-32%)
Severe decline -20.0%, PE contracts to 21.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.7 to 14.1
Stabilization Target:
$179.15
(+11.1%)
PE Expansion Potential:
+11.1%
Share & Embed Analysis
Last updated: May 14, 2026 3:40 PM ET
Data refreshes hourly during market hours. Next update: 4:40 PM
Data refreshes hourly during market hours. Next update: 4:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NBIX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Kyle Gano
SELL
36400 shares
2026-01-16
Leslie V Norwalk
SELL
1190 shares
2025-12-16
Leslie V Norwalk
SELL
5000 shares
2025-12-15
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$136 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$102 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 56 HOLD |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
11 analysts |
$40 | 57 HOLD |
Advanced NBIX Option Strategies
Professional options setups generated by AI based on today's NBIX price and gamma walls.
